EIKNEikon Therapeutics, Inc.

1. Aug 14, 2026EIK1001 – TLR7/8 Dual-Agonist.Regulation FD disclosure · press release
2. Aug 13, 2026Eikon Therapeutics Reports Second Quarter 2026 Financial Results.Earnings release · press release
3. Aug 3, 2026Effective July 31, 2026, Leon Chen, Ph.D. and Joshua Wolfe resigned from the Board of Directors of Eikon Therapeutics, Inc. (the “Company”). Dr. Chen’s and Mr. Wolfe’s resignations were not because of a disagreement with the Company on any matter relating to the Company’s operations, policies or practices.Director or officer change · Form 8-K
4. Jun 10, 2026On June 5, 2026, the Board of Directors (the “Board”) of Eikon Therapeutics, Inc. (the “Company”) appointed Ma. Fatima D. Francisco to the Board as a Class I director, effective June 15, 2026.Director or officer change · Form 8-K
5. Jun 1, 2026On May 30, 2026, the Company issued a press release announcing updated data on its Phase 2 trial of EIK1001 in first-line patients with stage 4 non-small cell lung cancer and new and updated data on its Phase 1/2 trial of EIK1003 in patients with advanced solid tumors, which were presented at the 2026 American Society …Regulation FD disclosure · Form 8-K
6. May 11, 2026Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates.Earnings release · press release
7. Mar 30, 2026Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates.Earnings release · press release
8. Feb 6, 2026Amendment and Restatement of Certificate of Incorporation In connection with the closing of the initial public offering (the “IPO”) of shares of common stock of Eikon Therapeutics, Inc. (the “Company”) on February 6, 2026, the Company filed an amended and restated certificate of incorporation (the “Restated …Charter/bylaw amendment or fiscal-year change · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.